TG Therapeutics, Inc. $TGTX Shares Bought by Profund Advisors LLC

Profund Advisors LLC boosted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 48.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 74,814 shares of the biopharmaceutical company’s stock after purchasing an additional 24,569 shares during the quarter. Profund Advisors LLC’s holdings in TG Therapeutics were worth $2,230,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Amalgamated Bank grew its position in TG Therapeutics by 1.1% during the 3rd quarter. Amalgamated Bank now owns 39,248 shares of the biopharmaceutical company’s stock worth $1,418,000 after purchasing an additional 424 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of TG Therapeutics by 1.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,406 shares of the biopharmaceutical company’s stock worth $1,135,000 after acquiring an additional 441 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of TG Therapeutics by 21.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 2,693 shares of the biopharmaceutical company’s stock worth $99,000 after acquiring an additional 467 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 486 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund boosted its stake in shares of TG Therapeutics by 1.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,062 shares of the biopharmaceutical company’s stock worth $926,000 after acquiring an additional 500 shares in the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

TGTX has been the topic of several recent analyst reports. Wall Street Zen lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. JPMorgan Chase & Co. lowered their target price on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research note on Monday, February 2nd. Weiss Ratings raised shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, May 1st. Zacks Research lowered shares of TG Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, May 1st. Finally, HC Wainwright increased their target price on shares of TG Therapeutics from $60.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.50.

TG Therapeutics Trading Down 0.1%

Shares of TG Therapeutics stock opened at $39.43 on Wednesday. The firm has a market capitalization of $6.04 billion, a PE ratio of 13.79 and a beta of 1.68. TG Therapeutics, Inc. has a twelve month low of $25.28 and a twelve month high of $44.65. The firm’s 50-day moving average price is $34.60 and its 200 day moving average price is $32.00. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). The company had revenue of $204.92 million during the quarter, compared to analysts’ expectations of $200.33 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The company’s quarterly revenue was up 69.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.03 earnings per share. On average, sell-side analysts predict that TG Therapeutics, Inc. will post 1.31 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.